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Elevated levels of circulating pro-inflammatory cytokines are associated with symptom-
ology of several psychiatric disorders, notably major depressive disorder. Symptomology 
has been linked to inflammation/cytokine-dependent induction of the Kynurenine 
Pathway. Galectins, like pro-inflammatory cytokines, play a role in neuroinflammation 
and the pathogenesis of several neurological disorders but without a clearly defined 
mechanism of action. Their involvement in the Kynurenine Pathway has not been investi-
gated. Thus, we searched for a link between galectins and the Kynurenine Pathway using 
in vivo and ex vivo models. Mice were administered LPS and pI:C to determine if galectins 
(Gal’s) were upregulated in the brain following in vivo inflammatory challenges. We then 
used organotypic hippocampal slice cultures (OHSCs) to determine if Gal’s, alone or with 
inflammatory mediators [interferon-gamma (IFNγ), tumor necrosis factor-alpha (TNFα), 
interleukin-1beta (IL-1β), polyinosine-polycytidylic acid (pI:C), and dexamethasone (Dex; 
synthetic glucocorticoid)], would increase expression of indoleamine/tryptophan-2,3- 
dioxygenases (DO’s: Ido1, Ido2, and Tdo2; Kynurenine Pathway rate-limiting enzymes). 
In vivo, hippocampal expression of cytokines (IL-1β, TNFα, and IFNγ), Gal-3, and Gal-9 
along with Ido1 and Ido2 were increased by LPS and pI:C (bacterial and viral mimetics). 
Of the cytokines induced in vivo, only IFNγ increased expression of two Ido1 transcripts 
(Ido1-FL and Ido1-v1) by OHSCs. Although ineffective alone, Gal-9 accentuated 
IFNγ-induced expression of only Ido1-FL. Similarly, IFNγ induced expression of several 
Ido2 transcripts (Ido2-v1, Ido2-v3, Ido2-v4, Ido2-v5, and Ido2-v6). Gal-9 accentuated 
IFNγ-induced expression of only Ido2-v1. Surprisingly, Gal-9 alone, slightly but signifi-
cantly, induced expression of Tdo2 (Tdo2-v1 and Tdo2-v2, but not Tdo2-FL). These 
effects were specific to Gal-9 as Gal-1 and Gal-3 did not alter DO expression. These 
results are the first to show that brain Gal-9 is increased during LPS- and pI:C-induced 
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inTrODUcTiOn
There is a widely accepted association between activation of the 
immune system and major depression, with a multitude of stud-
ies showing that elevated levels of pro-inflammatory cytokines 
are found within the circulation of patients with MDD (1). 
Furthermore, up to 45% of patients receiving immunotherapy 
(IFNα) for hepatitis C or cancer have a greater severity of symp-
toms of MDD (2, 3). Extensive work using rodent models has 
detailed the induction of depression-like behaviors, anhedonia 
(decreased sucrose preference), and helplessness/despair 
(increased immobility during forced-swim and tail-suspension 
tests) after administration of LPS, pI:C, or infection with 
Mycobacterium bovis (4–7). These immune activators induce 
neuroinflammation; however, the mechanism(s) linking inflam-
mation and depression is widely debated. One probable causal 
factor is altered tryptophan metabolism.
Elevated tryptophan metabolism to kynurenine (Kyn) via 
rate-limiting DO’s is correlated to the development of depression-
like behaviors in rodent models (8) and severity of depression 
behaviors in patients with MDD (2). Expression of all three DO 
enzymes (Ido1, Ido2, and Tdo2) is increased following activa-
tion of the immune system. Their expression is increased by 
LPS (mimicking a bacterial infection), pI:C (mimicking a viral 
infection), and administration of pro-inflammatory cytokines 
(8–15). In contrast, in the absence of Ido1 (knockout mice), 
inflammation-dependent depression-like behaviors are attenu-
ated (8, 16, 17). Inflammation-induced behavioral changes are 
largely attributed to increased Trp metabolism to Kyn followed 
by non-rate-limiting Kyn conversion to downstream neuroactive 
metabolites quinolinic acid (QuinA) and kynurenic acid (KynA) 
(5). QuinA and KynA bind to the N-methyl-d-aspartate and 
α7nAChR receptors to either enhance or decrease neurotransmit-
ter signaling, respectively. An imbalance of these two metabolites 
is linked to several neurological diseases (18–20).
Galectins are β-galactoside-binding proteins. Although 
their mechanism of action is still unclear, Gal-1, Gal-3, and 
Gal-9 are believed to play significant roles in neuropathology 
and neuroinflammation (21). Gal-1 is typically classified as 
anti-inflammatory and neuroprotective: suppressing IFNγ-
induced responses of microglia (22), glutamate neurotoxicity 
(23), and neurodegeneration (22). Gal-1 knockout mice 
are more susceptible to developing experimental autoim-
mune encephalomyelitis, a mouse model used to mimic MS 
symptomology. Gal-3 and Gal-9 both have context-specific 
immunomodulatory capabilities (24–28). As examples, Gal-3 
increases secretion of pro-inflammatory cytokines (26) from 
microglia and astrocytes, while Gal-9 is a potent chemoattract-
ant (29) and upregulates IFNγ production (30, 31).
A galectin–DO connection has not been directly linked to 
neuropsychiatric disorders, but there are several incidences of 
increased expression of both Gal-9 and Ido1. Increased expres-
sion of both Ido1 and Gal-9 are associated with MS (32–34), 
Grave’s disease, Hashimoto’s disease (35, 36), and rheumatoid 
arthritis (37, 38). Although the pathophysiology of these disor-
ders is still unclear, a synergy between Ido1 and Gal-9 may be 
a crucial uncharacterized mechanism involved in the initiation 
and/or severity of immune disorders.
Data suggest that Gal-1, Gal-3, and Gal-9 modulate neuroin-
flammation; however, there is no evidence directly connecting 
galectins to the Kynurenine Pathway. Thus, we determined whether 
galectins were increased in the mouse brain following peripheral 
administration of LPS or pI:C. We found that both Gal-3 and 
Gal-9 (plus DO’s) were increased in the mouse hippocampus dur-
ing neuroinflammation. We then decided to investigate whether 
the elevation in Gal-3 and Gal-9 were involved in the concurrent 
increase in expression of the rate-limiting enzymes metabolizing 
tryptophan to Kyn (the DO’s: Ido1, Ido2, and Tdo2) using organo-
typic hippocampal slice cultures (OHSCs). As we have previously 
shown (39), IFNγ induced Ido1 and Ido2 expression by OHSCs. 
Interestingly, Gal-9 was able to directly increase Tdo2 expression 
and increased both Ido1 and Ido2 expression in the presence of 
IFNγ. These are the first findings to link immunomodulatory 
galectin activity to the Kynurenine Pathway, potentially provid-
ing a new target for neuroinflammatory therapies. The ability to 
induce expression of the rate-limiting enzymes of the Kynurenine 
Pathway also defines a mechanism by which Gal-9 can mediate 
symptoms associated with several psychiatric conditions.
MaTerials anD MeThODs
Mice
C57BL/6J mice were maintained in the University of Illinois’s 
Institute for Genomic Biology animal facility. Procedures and 
animal care were in accordance with the Guide for the Care 
and Use of Laboratory Animals (National Research Council) and 
approved by the Institutional Animal Care and Use Committee. 
Young adult mice, used for neuroinflammation (intraperitoneal, 
i.p. LPS or pI:C) experiments, were 12-week-old males at time 
of treatment. Saline (control), LPS, or pI:C treatments were 
neuroinflammation. Increased expression of Gal-9 may be critical for neuroinflammation- 
dependent induction of DO expression, either acting alone (Tdo2-v1 and Tdo2-v2) or 
to enhance IFNγ activity (Ido1-FL and Ido2-v1). Although these novel actions of Gal-9 
are described for hippocampus, they have the potential to operate as DO-dependent 
immunomodulatory processes outside the brain. With the expanding implications of 
Kynurenine Pathway activation across multiple immune and psychiatric disorders, this 
synergy provides a new target for therapeutic development.
Keywords: galectin 9, iDO1, iFnγ, neuroinflammation, cytokines, kynurenine pathway
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administered prior to the start of the dark cycle. LPS (serotype 
0127:B8, Sigma, St. Louis, MO, USA) was administered at 
330 μg/kg body weight; this dose has been shown to elicit neu-
roinflammation, elevated Ido1, Ido2, and Tdo2 expression and 
depression-like behaviors (40). pI:C (P0913, Sigma, St. Louis, 
MO, USA) was administered at 12 mg/kg body weight. Previous 
work has shown that pI:C also causes cytokine and Ido1 response 
in the hippocampus and depression-like behaviors (6). Mice were 
sacrificed 6 h post-treatment.
cell culture reagents
Heat-inactivated horse serum (SH30074.03), Hank’s balanced salt 
solution (HBSS, SH30030.03), Eagle’s minimal essential medium 
(MEM, SH30024.02) were purchased from Hyclone (Logan, 
UT, USA). d-glucose (15023–021) was purchased from Gibco 
(Carlsbad, CA, USA). Dex (tested at 1 μM, D4902), pI:C (tested 
at 10  μg/ml, P0913), and Gey’s balanced salt solution (GBSS, 
G9779) were from Sigma (St. Louis, MO, USA). Recombinant 
mouse IFNγ (tested at 10  ng/ml, 315–05) was from Peprotech 
(Minneapolis, MN, USA). Gal-1 (1245), Gal-3 (1197), and 
Gal-9 (3535), all tested at 1 μg/ml and TNFα (tested at 10 ng/
ml, 410-MT) were purchased from R&D Systems (Minneapolis, 
MN, USA). IL-1β (tested at 10 ng/ml, IL014) was purchased from 
Chemicon International (Temecula, CA, USA).
Organotypic hippocampal slice cultures
Organotypic hippocampal slice cultures were prepared from 
hippocampi of C57BL/6J pups, 7–10  days old, as previously 
described (39). Briefly, hippocampi were cut into 350  μm 
transverse slices with a McIlwain tissue chopper (Campden 
Instruments Ltd., UK) and positioned onto membrane inserts 
(PICM03050, EMD Millipore) with six slices per insert, each 
slice from a different animal. Inserts were placed into 6-well 
culture plates with 1.25  ml of medium [50% MEM, 25% 
horse serum, 1 × penicillin/streptomycin (Pen/Strep), 15 mM 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES 
buffer, pH 7.4), 25% HBSS, and 0.5% d-glucose]. Every 
2–3 days, medium was changed. On the seventh day, OHSCs 
were rinsed three times with serum-free medium (Dulbecco’s 
MEM, Pen/Strep, HEPES and 150 μg/ml bovine serum albu-
min) and incubated for 2  h. Slices were rinsed again with 
serum-free medium and treatments added to fresh serum-free 
medium. OHSCs were treated with IFNγ, TNFα, IL-1β, pI:C, or 
Dex, with or without Gal-9. To determine if effects were specific 
to Gal-9, independent OHSC preparations were treated with 
IFNγ and pI:C with or without Gal-1 and Gal-3. Six hours later, 
tissues and supernatants were collected and kept at −80°C for 
subsequent analysis.
reverse Transcription  
and real-Time rT-Pcr
RNA was extracted using the EZNA. Total RNA Kit II (Omega 
Bio-Tek, Norcross, GA, USA) and cDNA was prepared with 
the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Grand Island, NY, USA). The cDNA was amplified 
to quantify steady-state gene expression by qPCR using TaqMan 
Universal PCR Master Mix and Prism 7900 thermocycler 
(Applied Biosystems, Foster City, CA, USA). Using the compara-
tive threshold cycle method (GAPDH used to normalize target 
gene expression), differences in cDNA levels were determined by 
comparing 2−ΔΔCts, Ct = cycle threshold (39).
DO Transcripts and qPcr assay Design
Our previous publication describes validated qPCR assays to 
quantify the expression of distinct DO transcripts in mouse 
tissues and OHSCs. Assays for Ido1 (Ido1-FL, Ido1-v1), Ido2 
(Ido2-FL, Ido2-v1, Ido2-v6, and Ido2-v3), and Tdo2 (Tdo2-FL, 
Tdo2-v1, and Tdo2-v2) were described (39). Gene structure for 
Ido1, Ido2, and Tdo2 is shown in Figure  1. Structures for the 
previously described transcripts are shown as well as the exon-
structure of additional Ido1 (Ido1-v2) and Ido2 variants (Ido2-v2, 
Ido2-v4, and Ido2-v5) that were quantified for the first time for 
this manuscript. Assay specifics for DO transcript analyses are 
shown in Table  1. Probe-based assays were purchased from 
IDT with custom assays fashioned using the IDT PrimerQuest® 
Design Tool. Correct amplicon size was confirmed by gel electro-
phoresis. Several transcripts (notably Ido1-FL) are not detectable 
in all naive mouse brain or control OHSC samples (Ct values 
“undetermined”), thus negating the ability to properly calculate 
relative gene expression: for mathematical analysis, a Ct value of 
40.0 was assigned when this occurred.
statistics
Data are reported as mean ± SEM for three to four independent 
OHSC preparations per treatment combination and six mice/
treatment group for the adult animal study. SigmaPlot 13.0 soft-
ware was used to conduct two-way analysis of variance (two-way 
ANOVA) using a 2 × 6 (OHSC) or 2 × 2 (in vivo) arrangement of 
treatments. In the presence of a significant interaction, assessed 
by Holm–Šídák method, post hoc analyses for multiple compari-
sons were performed. Comparisons were considered significant 
at p < 0.05.
resUlTs
In Vivo: neuroinflammation
LPS and pI:C Induce DOs, Cytokines, and Galectins 
in the Mouse Hippocampus
Ido1 Expression
LPS and pI:C were injected intraperitoneally into adult mice 
to determine if, along with the DO’s, brain galectin expres-
sion was regulated by neuroinflammation. Similar to previous 
studies (6, 13, 40), hippocampal Ido1 expression was increased 
within several hours of a LPS or pI:C challenge. Both LPS and 
pI:C induced all three Ido1 transcripts: Ido1-FL, Ido1-v1, and 
Ido1-v2 (all p  <  0.01; Figures  2A–C), with the greatest fold 
increase seen for Ido1-FL followed by Ido1-v2 (both transcripts 
essentially absent in the hippocampus of naive/control mice), 
but only a minor increase for the highly expressed Ido1-v1 (see 
relative basal Ct values in the figure legend).
Ido2 Expression
Several Ido2 transcripts are expressed in the mouse brain. 
Ido2-v1, Ido2-v3, and Ido2-v6 were increased in the hippocampus 
FigUre 1 | Murine ido1, ido2, and Tdo2 gene structure and transcripts. Structures of the three DO genes are shown to scale with spicing patterns illustrated 
for each gene. Ido1 and Ido2 are separated by 7733 bp (red line) on chromosome 8, while Tdo2 is situated on chromosome 3. As detailed previously (39), 
posttranslational modification of precursor mRNA results in several alternative spliced variants for each DO: full-length (FL) and variant (v) transcripts encoding 
variable size proteins (yellow regions within each transcript). Ensemble and NCBI databases were used to determine splicing patterns, with simplified names used in 
the manuscript shown to the left of database names. Within each gene, exons conserved across transcripts are shown in gray, while exons that vary by transcript 
are colored. Assays to quantify the expression of each transcript are described in Table 1. Exon span for each assay are shown (●  ●).
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following LPS treatment (all p < 0.05; Figures 3A,C,F), whereas 
only Ido2-v1 was elevated by pI:C (p < 0.05; Figure 3A). Using 
assays that specifically assess Ido2-FL, Ido2-v2, Ido2-v4, and 
Ido2-v5 (Table 1), we found that their expression was not induced 
by either LPS or pI:C (Figures 3B,D,E). Ido2-FL was not detect-
able nor induced (not shown).
Tdo2 Expression
Tdo2-FL expression was not altered by LPS or pI:C (Figure 4A); 
however, both Tdo2-v1 and Tdo2-v2 were increased by pI:C 
(p < 0.05, Figures 4B,C).
Cytokines
Illustrating a classical neuroinflammatory response (13, 41), 
both LPS and pI:C increased IFNγ, TNFα, and IL-1β expres-
sion in the mouse hippocampus (all p  <  0.05; Figures  5A–C). 
Gal-1 was expressed, but not induced by LPS or pI:C 
(Figure  5D), while Gal-3 expression was doubled by LPS and 
pI:C (p < 0.05, Figure 5E). Interestingly, Gal-9 expression was 
increased ~ 4-fold by LPS and ~10-fold by pI:C (all p < 0.001, 
Figure 5F).
In Vivo Summary
These data illustrate that neuroinflammation increased the 
expression of Gal-3 and Gal-9 along with the expected increase 
in pro-inflammatory cytokines. Galectin and cytokine induction 
was accompanied by elevated DO expression within the mouse 
hippocampus, but in a DO and transcript-specific manner. Thus, 
we next investigated which (if any) of the induced cytokines 
or galectins directly mediated the changes in hippocampal DO 
expression, using OHSCs.
Ex Vivo: Ohscs
Gal-9 Synergized with IFNγ to Induce Ido1-FL 
Expression
As shown previously, IFNγ induced Ido1-FL (9, 39) and Ido1-v1 
expression (39) by OHSCs (p < 0.001; Figures 6A,B). Gal-9 alone 
did not induce expression of any Ido1 transcript; however, Gal-9 
TaBle 1 | assay specifics for analysis of murine ido1, ido2, and Tdo2 steady-state gene expression.
Transcript exon span assay iD or custom name Primer/probe sequence amplicon (bp)
ido1-Fl 1-3-4  Mm.PT.42.8645095 Forward TTTGCTCTACCACATCCACTG 117
Probe 6-FAMCAGATTTCTZenAGCCACAAGGACCCAGGIABkFQ
Reverse GCAGCTTTTCAACTTCTTCTCG
ido1-v1 2-3  Ido1-v ex 2-3 Forward GACCCCGGACGGTAAAATTAT 138
Probe 6-FAMTCGGGCAGCZenTCCACATTACAATTCAIABkFQ
Reverse TCTCAATCAGCACAGGCAG
ido1-v2 2b-3-4-5  Ido1-X2-mouse Set 1 Forward CGGACGGTGGAGCTG 256
Probe 6-FAMATTGAGAACZenGGGCAGCTTCGAGAAIABkFQ
Reverse CGCAGTAGGGAACAGCAATA
ido2-Fl 1-2-4  Mm.PT.42.8856312 Forward GGAGATACCACATTTCTGAGGA 114
Probe 6-FAMCCAGAGGATZenTTGGAAGGAGAAAGCCATIABkFQ
Reverse CGATTAAGTGAGGAAGTCTGAGG
ido2-v1 3-4  Ido2-v ex 3-4 Forward GGACTTTACATCCCTAACCTCAC 131
Probe 6-FAMCCTCAGCTTZenCTCGAACCCTGTAACTGTAIABkFQ
Reverse CTGCTCACGGTAACTCTTTAGG
ido2-v2 3′-4  Ido2-X4 Set 4 Forward AAGCCTGCGGAGCAAAG 88
 Ido2-X2-mouse Set 1 Probe 6-FAMTGAAGAGATZenGAGCAATGAGCCGGTIABkFQ
 Ido2-v2-ex3-4 set2 Reverse GAGGCATCTGTCCTGCCT
ido2-v3 4-5′-6-7  Ido2-v4-Mz Set1 Forward CCCCAAAAGGTATCCAGGAACT 107
Probe 6-FAMCTGACCTGGZenTGCTGACAAACTGGAIABkFQ
Reverse ACTGATTTCCAACGGTCCTTCT
ido2-v4 1-4-5  Ido2-X1b-mouse Set 2 Forward CCAAATCCTCTGATGCCTCTC 148
Probe 6-FAMTAAAGAGTTZenACCGTGAGCAGCGCCIABkFQ
Reverse AAAGGTGCTGCCAAGATCTC
ido2-v5/v2 3′-5  Ido2-X2-mouse Set 1 Forward AAGCCTGCGGAGCAAAG 244/253
Probe 6-FAMTGAAGAGATZenGAGCAATGAGCCGGTIABkFQ
Reverse CCAAGTTCCTGGATACCTCAAC
ido2-v6/v2 3′-4  Ido2-v2-ex3-4 set2 Forward GAGCTGAAGAGATGAGCAATGA 85/85
Probe 6-FAMAGGACAGATZenGCCTCTCCTGGACTIABkFQ
Reverse ACGGTAACTCTTTAGGAATCTGC
Tdo2-Fl/v1 1-2  Mm.PT.42.9084201.g Forward CCTGAGACACTTCAGTACTATGAG 99/99
Probe 6-FAMCCCGTTTGCZenAGGAAACAGTGTAGGAIABkFQ
Reverse CTGTCTTCTTCATTGTCCTCCA
Tdo2-v1 0a-0b-1  Tdo2 variant1 exons 0a 0b-1.2 Forward CCAGTACGAAATGAGATCCGG 132
 Mm.PT.42.9084201.g Probe 6-FAMAGACACAGCZenCAATCAGCACCCAIABkFQ
Reverse AGGTTTGCTAGGTCAGGAATG
Tdo2-v2 0a-2  Tdo2 variant2 exons 0a 1.2 Forward GAAATGAGATCCGGGCTAAGAG 78
Probe 6-FAMTGGGTGCTGZenATTGGCTGTGTCTIABkFQ
Reverse GTGTATCTTTTATGTATCCTGATTGCC
Probe-based qPCR assays were purchased from IDT. The IDT PrimerQuest® Design Tool was used to design custom assays. Assay specifics: location of exons spanned, assay ID, 
primer/probe sequences, and amplicon size (confirmed by gel electrophoresis) are shown. The transcript Ido2-v2 is detected by three assays: Ido2-X4 Set 4, Ido2-X2-mouse Set 1, 
and Ido2-v2-ex3-4 set2. However, the assay Ido2-X4 Set 4 spans an exon boundary unique to the Ido2-v2 transcript. Discerning changes in Ido2-v2 expression is possible using this 
assay. In addition, since the assays that assess Ido2-v5/v2 and Ido2-v6/v2 also detect Ido2-v2, changes in Ido2-v5 and Ido2-v6 can only be estimated based on unique changes in 
gene expression using either Ido2-X2-mouse Set 1 or Ido2-v2-ex3-4 set2 compared to Ido2-X4 Set 4. Similarly, the entire Tdo2-FL sequence in found within Tdo2-v1, and as such, it 
is not possible to generate an assay specific to Tdo2-FL. However, the current data and our published work (39) strongly indicate that these transcripts are differentially regulated. 
Colored fonts are used to match the gene coloration in the graphic Figure 1 and data figures throughout the manuscript.
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significantly interacted with IFNγ to accentuate IFNγ-induced 
Ido1-FL expression [F(5,24)  =  8.02, MSE  =  1418, p  <  0.001, 
Figure  6A]. In contrast, Ido1-v2 was not induced by IFNγ or 
Gal-9 (Figure 6C), despite being inducible in  vivo.
Based on our in vivo results showing Gal-1 and Gal-3 expres-
sion within mouse hippocampus, we tested for Gal-9 specificity 
by treating OHSCs with Gal-1 or Gal-3. Surprisingly, considering 
their immunomodulatory capabilities, Gal-1 and Gal-3 did not 
alter Ido1 expression alone or in the presence of IFNγ (Figure 6, 
insets), suggesting that the synergy with IFNγ was Gal-9-specific. 
An additional degree of specificity is illustrated by the inability 
of TNFα, IL-1β, pI:C, or Dex to induce any Ido1 transcript or 
to synergize with galectins. Thus, the elevated expression of 
IFNγ and Gal-9 associated with neuroinflammation in  vivo 
would be expected to act synergistically to enhance Ido1-FL 
expression.
Gal-9 Synergized with IFNγ to Induce the Expression 
of Ido2-v1
Similar to our previous publication (39), both IFNγ and 
pI:C induced expression of Ido2-v1 and Ido2-v3 (p  <  0.001; 
Figures 7A,C), but only IFNγ increased expression of Ido2-v6/v2 
(p < 0.001; Figure 7F). Interestingly, Gal-9 synergized with IFNγ 
to accentuate only Ido2-v1 expression [F(5,24) = 4.02, MSE = 30.0, 
p  <  0.01, Figure  7A]. Three additional Ido2 variants were 
expressed by OHSCs. IFNγ induced Ido2-v4 and Ido2-v5 expres-
sion (p < 0.05, Figures 7D,E), but not Ido2-v2 (Figure 7B). These 
data suggest that each Ido2 transcript is differentially regulated. 
FigUre 2 | In vivo, hippocampal ido1 expression is increased after lPs and pi:c administration. Mice were administered saline (Ctrl), LPS, or pI:C and 
hippocampi collected after 6 h. Gene expression of three Ido1 transcripts was measured. Expression levels are relative to Ctrl samples normalized to 1.0. *p < 0.05 
for the effect of LPS or pI:C. Average Ctrl Ct values for each transcript: (a) Ido1-FL: Ct = 40.0, (B) Ido1-v1: Ct = 29.8, and (c) Ido1-v2: Ct = 39.7. Ct values indicate 
that Ido1-FL and Ido1-v2 are essentially not expressed in naive (Ctrl) mouse hippocampi, whereas Ido1-v1 expression is detectable in all samples.
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In addition, neither TNFα, IL-1β, nor Dex increased Ido2 expres-
sion, alone or with Gal-9. Gal-1 and Gal-3 did not affect Ido2 
expression (Figure  7; insets). Thus, the elevated expression of 
IFNγ and Gal-9 associated with neuroinflammation in vivo would 
be expected to act synergistically to enhance Ido2-v1 expression.
Gal-9 Induced Tdo2-v1 and Tdo2-v2
All three Tdo2 transcripts are well-expressed by OHSCs 
(Figure 8, Ct’s presented in figure legend). Neither IFNγ, TNFα, 
IL-1β nor pI:C affect Tdo2 expression (all three transcripts), 
although Dex has a specific inductive action on the Tdo2-FL 
transcript [p  <  0.05, Figure  8A; as previously reported (39)]. 
Gal-9 did not affect the expression of Tdo2-FL, but Gal-9 slightly, 
and significantly increased expression of both Tdo2-v1 and 
Tdo2-v2 (p  <  0.05; Figures  8B,C). Neither Gal-1 nor Gal-3, 
alone or in combination with inflammatory mediators, affected 
Tdo2 expression (Figure 8, insets). Thus, the elevated expression 
of Gal-9 associated with neuroinflammation in  vivo would be 
expected to enhance Tdo2-v1 and Tdo2-v2 expression within the 
hippocampus; whereas Tdo2-FL is specifically induced by the 
glucocorticoid receptor agonist, Dex.
Gal-9 Increased TNFα and IL-6 Expression
Previous work had shown that Gal-9 can increase production of 
pro-inflammatory cytokines, such as TNFα from microglia (24). 
To validate this immunomodulatory action, we investigated the 
ability of our treatments, including Gal-9, to induce an inflamma-
tory response by OHSCs. Gal-9, IFNγ, and pI:C induced TNFα 
expression (p < 0.05; Figure 9A), while Gal-9, pI:C, and IL-1β 
induced IL-6 expression (p < 0.05; Figure 9B). As expected, Dex 
decreased TNFα expression, acting in a typical anti-inflammatory 
(glucocorticoid-like) manner (p  <  0.05). Only pI:C increased 
expression of Gal-9 (p  <  0.05); this induction was diminished 
by Gal-9 (p < 0.05; Figure 9C). Of note, none of the treatments 
(or combinations) resulted in detectable expression of IFNγ by 
OHSCs (not shown). Thus, IFNγ responsible for Ido1 and Ido2 
expression is not derived from cells resident in the hippocampal 
parenchyma, while, in contrast, Gal-9 is expressed by the brain.
DiscUssiOn
We previously reported an inflammation-by-stress synergy 
(IFNγ × glucocorticoid) that functions to accentuate expression 
of Ido1-FL, Ido1-v1, and Ido2-v3 within the mouse hippocampus 
(39). We now report another exciting synergistic interaction 
between two immunomodulatory factors: IFNγ and Gal-9 that acts 
to enhance Ido1-FL and Ido2-v1 expression. These data indicate 
that IFNγ drives Ido1 and Ido2 induction, but secondary factors 
determine which transcripts mediate the synergistic induction of 
the Ido’s. We also describe assays to quantify expression of multi-
ple Ido1 and Ido2 transcripts in vivo (during neuroinflammation) 
and ex vivo (during inflammatory challenges of OHSCs).
In vivo, LPS or pI:C induced neuroinflammation (i.e., increased 
cytokine expression) and galectin expression, which was accom-
panied by increased expression of all Ido1 transcripts, but only 
specific Ido2 and Tdo2 transcripts. This is the first report dem-
onstrating that both LPS- and pI:C-induced neuroinflammation 
involved increased Gal-3 and Gal-9 expression: paralleling the 
elevated expression of IFNγ, TNFα, and IL-1β. Thus, we treated 
OHSCs with these cytokines  ±  galectins to determine which 
factors (or combination thereof) were responsible for elevated 
DO expression in vivo. Using OHSCs, we found that Gal-9 acted 
independently to increase Tdo2-v1 and Tdo2-v2 expression, but 
Gal-9 only increased expression of Ido1 and Ido2 in the presence 
of IFNγ. These findings suggest that Gal-9 plays a previously 
undefined role in the induction of the Kynurenine Pathway.
FigUre 3 | specific ido2 transcripts expressed in the mouse hippocampus are increased by lPs and pi:c in vivo. Mice were administered saline (Ctrl), 
LPS, or pI:C and hippocampi were collected after 6 h. Expression of six Ido2 gene transcripts was measured. Expression levels are relative to Ctrl samples set to 
1.0. *p < 0.05 for the effect of LPS or pI:C. Average Ctrl Ct values for each transcript: (a) Ido2-v1: Ct = 29.2, (B) Ido2-v2: Ct = 28.9, (c) Ido2-v3: Ct = 28.4, 
(D) Ido2-v4: Ct = 38.5, (e) Ido2-v5/-v2: Ct = 31.6, and (F) Ido2-v6/-v2: Ct = 28.3. Ct values indicate that Ido2-FL (non-detectable, not shown) and Ido2-v4 are 
essentially not expressed in naive (Ctrl) mouse hippocampi. Expression of other Ido2 transcripts are readily detectable in all samples.
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ido1
We previously detailed the regulation of two Ido1 transcripts and 
compared their relative expression across multiple areas of the 
brain. Ido1-v1 was well expressed (39) in the mouse hippocam-
pus and other brain regions, whereas Ido1-FL is low/undetectable 
across the naive mouse brain (39). Like Ido1-FL, we now show that 
a third Ido1 transcript, Ido1-v2, is low/undetectable in the mouse 
hippocampus of naive mice (Figure 2). Not only is hippocampal 
basal expression of these three Ido1 transcripts different but also 
the regulation of Ido1 transcripts by inflammatory mediators 
and corticosteroids is unique as well. Expression of both Ido1-FL 
and Ido1-v2 were induced by LPS and pI:C in  vivo (current 
work), but not ex vivo (39), suggesting that in vivo hippocampal 
responses to LPS and pI:C must be mediated by other secondary 
factors: presumably, cytokines and other immunomodulatory 
mediators. Using OHSCs, we found that only IFNγ was able to 
directly induce Ido1-FL and Ido1-v1 expression [Figure 6; (39)]. 
Since brain/hippocampal IFNγ is inducible by LPS and pI:C, but 
OHSCs did not express IFNγ (not shown), non-resident cells 
from the periphery are probably responsible for the elevated IFNγ 
expression within the brain that occurs in vivo and thus for the 
increase in Ido1 expression. Indeed, during neuroinflammation, 
IFNγ+ cells infiltrate the brain (42). Hippocampal Ido1-v2 expres-
sion is increased by LPS and pI:C in vivo; however, we have not, as 
yet, identified the mechanism responsible for this response; none 
of the treatments including IFNγ increased Ido1-v2 expression 
by OHSCs.
In the naive hippocampus and control OHSCs, only Ido1-v1 
is readily detectable, but Ido1-v1 expression is far less sensitive 
to pro-inflammatory induction compared to Ido1-FL. These data 
suggest that Ido1-v1 probably has a major role in basal metabo-
lism [supplying Kyn for nicotinamide/NAD+ synthesis (43)], 
whereas the sizeable induction of Ido1-FL by IFNγ plus either 
Gal-9 (current work) or glucocorticoids (39) is necessary to meet 
the increased energy/NAD+ demand associated with inflamma-
tion (44–46) or stress, respectively (Figure 10). Indeed, elevated 
central nervous system NAD+ levels during experimental MS 
(47) are associated with increased Ido1 (48). An unfortunate 
FigUre 5 | lPs and pi:c increase expression of pro-inflammatory cytokines and galectins in the mouse hippocampus. Mice were administered saline 
(Ctrl), LPS, or pI:C and hippocampi were collected after 6 h. Gene expression of (a) IFNγ, (B) TNFα, (c) IL-1β, (D) Gal-1, (e) Gal-3, and (F) Gal-9 was measured 
and expression is shown relative to Ctrl. *p < 0.05 for main effect of LPS or pI:C.
FigUre 4 | In vivo, hippocampal Tdo2 expression is increased after pi:c administration. Mice were administered saline (Ctrl), LPS, or pI:C and hippocampi 
were collected after 6 h. Gene expression of three Tdo2 transcripts was measured. Expression is relative to Ctrl, normalized to 1.0. *p < 0.05 for the effect of pI:C. 
Average Ctrl Ct values for each transcript: (a) Tdo2-FL: Ct = 21.4, (B) Tdo2-v1: Ct = 28.7, and (c) Tdo2-v2: Ct = 27.7. Ct values indicate that all three Tdo2 
transcripts are well-expressed in the mouse hippocampus.
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FigUre 6 | iFnγ increases expression of two ido1 transcripts with gal-9 interacting to accentuate only ido1-Fl ex vivo. OHSCs were treated with IFNγ, 
TNFα, IL-1β, pI:C, and Dex ± Gal-9. Additional OHSCs (insets) were treated with IFNγ and pI:C ± Gal-1 or Gal-3. Gene expression of three Ido1 transcripts was 
measured and expression levels are relative to Ctrl samples normalized to 1.0. *p < 0.05 for the effect of IFNγ. δp < 0.05 for Gal-9 within inflammatory mediator. 
Average Ctrl Ct values for each transcript: (a) Ido1-FL: Ct = 40.0, (B) Ido1-v1: Ct = 34.9, and (c) Ido1-v2: Ct = 40.0. Ct values indicate that only Ido1-v1 is 
expressed in Ctrl slice cultures, paralleling the relative expression pattern of mouse hippocampi (Figure 2).
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FigUre 7 | iFnγ increases expression of five ido2 transcripts with gal-9 interacting to accentuate only ido2-v1 ex vivo. OHSCs were treated with IFNγ, 
TNFα, IL-1β, pI:C, and Dex ± Gal-9. Additional OHSCs (insets) were treated with IFNγ and pI:C ± Gal-1 or Gal-3. Gene expression of six Ido2 transcripts was 
measured, and expression levels are relative to Ctrl’s normalized to 1.0. *p < 0.05 for the effect of IFNγ. δp < 0.05 effect of Gal-9 within inflammatory mediator. 
Average Ctrl Ct values for each transcript: (a) Ido2-v1: Ct = 32.9, (B) Ido2-v2: Ct = 30.6, (c) Ido2-v3: Ct = 34.4, (D) Ido2-v4: Ct = 40.0, (e) Ido2-v5/-v2: Ct = 36.1, 
and (F) Ido2-v6/-v2: Ct = 33.7. Ct values indicate that Ido2-FL (non-detectable, not shown) and Ido2-v4 are not expressed in Ctrl slice cultures, similar to the 
hippocampus of naive (Ctrl) mice (Figure 3).
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consequence of Ido1 induction is elevated production and release 
of downstream neuroactive Kyn metabolites (QuinA and KynA) 
that mediate depression-like, anxiogenic, and adverse cognitive 
behaviors (49).
ido2
We recently found that several Ido2 transcripts are differentially 
expressed across the mouse brain, and again, inflammatory 
mediators and corticosteroids differentially regulate Ido2 tran-
scripts (39). Obviously, posttranslational processing of Ido2 (and 
Ido1) is not a random process but is utilized to fine-tune mRNA 
expression. A switch in posttranslational processing of Ido2 was 
first addressed using macrophages and B-cells, wherein both cell 
types can switch from expression of predominantly Ido2-FL to 
predominantly Ido2-v3 (50). While investigating Ido2 expression 
in the brain, we had first shown that LPS increased hippocampal 
Ido2 expression in vivo, using an assay that simultaneously quan-
tified all Ido2 transcripts (40). In the current work, we refined 
our understanding of central Ido2 expression by quantifying the 
regulation of its various transcripts. During in vivo neuroinflam-
mation, LPS and pI:C increased hippocampal Ido2 expression 
in a transcript-specific manner. Both LPS and pI:C increased 
Ido2-v1 expression; however, only LPS increased Ido2-v3 and 
Ido2-v6/v2. Since LPS and pI:C were administered intraperi-
toneally, we used OHSCs to identify direct versus indirect 
mechanisms responsible for Ido2 induction.
Together with our previous work (39), OHSC expression of 
Ido2-v1 and Ido2-v3 was increased by IFNγ, LPS, and pI:C, while 
FigUre 8 | Dex increases Tdo2-Fl, whereas gal-9 increases Tdo2-v1 and Tdo2-v2 expression ex vivo. OHSCs were treated with IFNγ, TNFα, IL-1β, pI:C, 
and Dex ± Gal-9. Additional OHSCs (insets) were treated with IFNγ and pI:C ± Gal-1 or Gal-3. Gene expression of Tdo2 transcripts was measured and levels are 
normalized to 1.0 for Ctrl within each transcript. p < 0.05 for the effect of Dex. ϕp < 0.05 for the main effect of Gal-9. Average Ctrl Ct values for each transcript: 
(a) Tdo2-FL: Ct = 29.1, (B) Tdo2-v1: Ct = 26.3, and (c) Tdo2-v2: Ct = 25.3. Ct values indicate that all three Tdo2 transcripts are well-expressed in mouse 
hippocampal slice cultures, paralleling their expression pattern in the naive mouse hippocampus (Figure 4).
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FigUre 9 | gal-9 increases expression of pro-inflammatory mediators and downregulates its own expression ex vivo. OHSCs were treated with IFNγ, 
TNFα, IL-1β, pI:C, and Dex ± Gal-9. Expression of (a) TNFα, (B) IL-6, and (c) Gal-9 was quantified. Expression for Ctrl cultures was normalized to 1.0. *p < 0.05 for 
the effects of IFNγ, pI:C, IL-1β, and Dex. ϕp < 0.05 for the main effect of Gal-9. δp < 0.05 effect for Gal-9 within inflammatory mediator. IFNγ expression was not 
detected in OHSCs.
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FigUre 10 | Proposed model for Kynurenine Pathway activation in the brain. Multiple studies have shown that in vivo administration of LPS or pI:C to mice 
increased peripheral pro-inflammatory cytokines (including IFNγ, TNFα, and IL-1β). These circulating cytokines, as well as immune cells that produce them, can enter 
the brain, to stimulate brain parenchymal production of additional immunomodulatory agents (cytokines and galectins). Gal-9 (produced within the brain or from the 
circulation) and IFNγ (from the circulation or infiltrating immune cells) synergize to increase expression of DO transcripts in the brain. Ex vivo, IFNγ is added [since 
brain parenchyma (i.e., OHSCs) does not express this cytokine], Gal-9 is also added to directly test its activity (but Gal-9 is expressed by cells resident to the brain). 
Independent of the source, IFNγ and Gal-9 increase DO expression in a DO- and transcript-specific manner, modeling in vivo responses. DO induction would 
increase flux down the Kynurenine Pathway to serve two purposes: supplying NAD+ for the brain, but with consequences (metabolites, Kyn, KynA, and QuinA, 
modulate behavior and immune activity).
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Ido2-v4, Ido2-v5, and Ido2-v6 were increased slightly but by only 
IFNγ. These data indicate that LPS and pI:C may act directly or 
via IFNγ to induce Ido2-v1 and Ido2-v3 within the hippocampus. 
In contrast, in vivo induction of Ido2-v4, Ido2-v5, and Ido2-v6 
are mediated by IFNγ. Uniquely, Ido2-v2 is highly expressed, but 
unaffected by inflammatory mediators and galectins. Overall, in 
both the mouse hippocampus and OHSCs, Ido2-v1 and Ido2-v3 
are most susceptible to induction by inflammation, whereas 
the other transcripts are either unchanged in  vivo or modestly 
induced ex vivo. These data suggest that Ido2-v1 and Ido2-v3 
induction was necessary to increase flux down the Kynurenine 
Pathway (Figure  10) to meet the increased energy (NAD+) 
demand associated with inflammation (44–46). A repercussion 
of their induction may be altered behaviors associated with Kyn 
production (50) and conversion to QuinA or KynA (20). Other 
Ido2 transcripts are relatively intractable and involved in basal 
metabolism.
gal-9
Excitingly, in the presence of IFNγ, Gal-9 accentuated Ido1-FL 
and Ido2-v1 expression by OHSCs; neither Gal-1 nor Gal-3 
affected DO expression. This statistical interaction suggests that 
Ido1 and Ido2 are regulated in a transcript-specific manner by 
additional factors: glucocorticoids (39) and Gal-9 (current work). 
Although IFNγ initiates Ido1-FL and Ido2-v1 induction [and 
indeed IFNγ action is necessary for neuroinflammation-induced 
Ido induction (10)], full induction in vivo requires synergy with 
glucocorticoids or Gal-9. As Gal-9 is expressed in many cell types 
within the brain, expression and induction of hippocampal Gal-9 
can occur via activation of cells resident to the brain. Gal-9 can 
bind to many cell surface partners including the T-cell immuno-
globulin and mucin-domain containing-3 (TIM-3) receptor, as 
well as directly associating with several transcription factors (51) 
within the cell. Further analysis is required to define which of 
these possible mechanisms are responsible for Gal-9’s ability to 
enhance IFNγ-induced DO expression.
There are multiple autoimmune disorders associated with 
elevated levels of both Ido1 and Gal-9 (32, 34–38). As Ido2 func-
tion is associated with the development of severe rheumatoid 
arthritis symptoms (52), Gal-9’s ability to enhance Ido2 expres-
sion may promote the development or severity of symptoms of 
rheumatoid arthritis or other autoimmune conditions. Thus, 
further characterization of the synergy between IFNγ and Gal-9 
during the induction of Ido1 and Ido2 is important to our under-
standing the pathophysiology of autoimmune disorders such as 
MS, Hashimoto’s disease, or rheumatoid arthritis. Similarly, Gal-9 
is an important regulator of the immune system, promoting the 
differentiation of T regulatory cells (53) and modulating viral 
pathogenesis (54). Ido1 plays a similar role in T cell differentiation 
(55) and also modulates viral pathogenesis (56). These findings 
open that possibility that one of the mechanisms by which Gal-9 
controls T cell differentiation and viral pathogenesis is its ability to 
direct DO expression. These links warrant further investigation.
Tdo2
Three Tdo2 transcripts are expressed in the mouse brain, only 
Tdo2-FL is enriched in hippocampus (39, 57). Similar to Ido1 
and Ido2, this specific enrichment implies a distinct regulatory 
mechanism for transcript expression. Although Tdo2-v1 and 
Tdo2-v2 expression was increased in the hippocampus post-
pI:C administration to mice, treatment of OHSCs with pI:C, 
pro-inflammatory cytokines or LPS (39) did not increase Tdo2 
expression. Thus, another factor(s) must mediate increased Tdo2 
expression in vivo. Using OHSCs, Tdo2-v1 and Tdo2-v2 expression 
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was increased by Gal-9. Since pI:C was a more potent inducer of 
hippocampal Gal-9 compared to LPS in vivo, the ability of pI:C 
administration to increase Tdo2-v1 and Tdo2-v2 expression may 
be mediated by central Gal-9 induction. In contrast to Tdo2-v1 
and Tdo2-v2, Tdo2-FL expression was increased by glucocorti-
coids (Dex and corticosterone) in OHSCs [Figure 8; (39)], but 
not cytokines or Gal-9. Thus, like the Ido’s, Tdo2 evolved to permit 
differential transcript expression in a stress- and inflammation-
specific manner within the brain. Tdo2-FL expression is depend-
ent on glucocorticoid activity; whereas Tdo2-v1 and Tdo2-v2 are 
responsive to Gal-9. These data suggest that different promotors 
used for Tdo2 induction (58) are necessary to meet the increased 
metabolic (NAD+) demand (Figure  10) associated with stress 
(Tdo2-FL) and neuroinflammation (Tdo2-v1 and Tdo2-v2), as 
previously suggested (44–46). A repercussion of aberrant Tdo2 
expression may be altered behavior such as those associated with 
schizophrenia (59, 60) and anxiety (61, 62).
cOnclUsiOn
This is the first manuscript to link Gal-9 to the Kynurenine 
Pathway. Following LPS and pI:C administration, IFNγ and 
Gal-9 expression are induced within the mouse hippocampus, 
as are Ido1 and Ido2. Using OHSCs, we clearly show that these 
two inflammatory modulators act in synergy to increase Ido1 
and Ido2 expression. This ex vivo synergism presumably has a 
role during in vivo induction of Ido1 and Ido2 (Figure 10). Since 
changes in Gal-9, IFNγ, and Ido1 expression have been inde-
pendently linked to central diseases such as depression and MS 
(2, 32, 34, 63), the ability of Gal-9 to accentuate DO expression 
during neuroinflammation may play a significant role in these 
and other psychiatric conditions and should be further studied 
as a putative therapeutic target. Finally, the action of Gal-9 is 
highly specific to the induction of distinct Ido1, Ido2, and Tdo2 
transcripts, suggesting complex posttranslational control over 
DO expression. Our understanding of this process is in its 
infancy. Additional work is required to clarify the relevance of 
DO expression to psychiatric illness, autoimmune disorders, and 
neurological disease.
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